Abstract

We describe a 50 year old male patient who was histologically diagnosed to have acinar cell tumour of pancreas. He initially presented with localized pancreatic cancer. He underwent distal pancreatectomy with splenectomy for pT3pNxpMxR1 disease, confirming acinar cell tumour. He was started on adjuvant chemotherapy with Gemcitabine but was discontinued after 2 cycles due to anaphylaxis. On disease relapse, Oxaliplatin plus Capecitabine was started but stopped after 5 cycles because of disease progression. But surprisingly a later CT scans after 3 months showed disease response which continued for almost 6 months without any treatment. We think this was an unusual late response. But unfortunately his disease progressed again shortly after this. At that time we re-challenged him with the same chemotherapy. More than three years from his initial diagnosis, this patient is still on maintenance treatment showing further clinical and radiological improvement in his disease.

Keywords: Maintenance Therapy; Pancreatic Acinar Cell Carcinoma (PACC); Gemcitabine; Oxaliplatin; Capecitabine

References

1. Solcia E., et al. “Tumors of the pancreas”. In: Atlas of Tumor Pathology; 3^rd Series, fascicle 20. Washington, DC, USA: AFIP, Armed Forces Institute of Pathology (1997): 103-114.
2. Handley ER., et al. “Pancreatic acinar cell carcinoma. Brigham RAD Case Lists”. Harvard Medical School, Department of Radiology, Brigham and Women's Hospital (2006).
3. Aqel B., et al. “Recurrent pancreatitis due to a cystic pancreatic tumor: a rare presentation of acinar cell carcinoma”. Journal of Pancreas 5 (2004): 151-154. 
4. Data were provided by the Office for National Statistics on request (2012). 
5. Data were provided by ISD Scotland on request (2012). 
6. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit on request (2012). 
7. Data were provided by the Northern Ireland Cancer Registry on request (2012). 
8. Raimondi S., et al. “Epidemiology of pancreatic cancer: an overview”. Nature Reviews Gastroenterology and Hepatology 6 (2009): 699-708.
9. Sultana A., et al. “Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer”. Journal of Clinical Oncology 25 (2007): 2607-2615.
10. Ashley SW and Lauwers GY. “Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2002. A 69-year old man with painful cutaneous nodules, elevated lipase levels, and abnormal results on abdominal scanning”. The New England Journal of Medicine 347 (2002): 1783-1791.
11. Klimstra DS., et al. “Acinar cell carcinoma of the pancreas. A clinicopathological study of 28 cases”. The American Journal of Surgical Pathology 16 (1992): 815-837. 
12. Yip D., et al. “Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer”. The Cochrane Database of Systematic Reviews 3 (2006): CD00209.
13. Cunningham D., et al. “Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer”. Journal of Clinical Oncology 27 (2009): 5513-5518.
14. Heinemann V., et al. “Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer”. BMC Cancer 8 (2008): 82.
15. V Hess., et al. “Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial”. Annals of Oncology 21 (2010): 2390-2395. 
16. Monique Antoine., et al. “Long-Term Survival in a Patient with Acinar Cell Carcinoma of Pancreas. A Case Report and Review of Literature”. Pancreas Journals 8.6 (2007): 783-789.
17. Vhmielecki J., et al. “Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes”. Cancer Discovery 4.12 (2014): 1398-1405. 

Citation

Citation: Shahid Gilani and Apurna Jegannathen. “A Sustained Response of Maintenance Therapy in Pancreatic Acinar Cell Carcinoma (PACC): A Case Report and Literature Review”.Acta Scientific Cancer Biology 4.9 (2020): 23-26.

Copyright

Copyright: © 2020 Shahid Gilani and Apurna Jegannathen This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.